The inability to identify the best clinical trial sites is a big problem – and one of the major challenges negatively affecting drug pricing and sponsors, says CEO.
Healthcare organizations that have clinical data on cancer trials need to share that information with global researchers to advance investigations into solving the disease.
A first-of-its-kind, new option for treating a form of eye cancer is now in its first phase-1 clinical research trial at Wills Eye Hospital in Philadelphia. The treatment, called light-activated AU-011 is an investigational drug that targets and aims to selectively destroy malignant cancer cells in patients who have life-and vision-threatening eye cancer.